Biomarker technologies market projected to hit $103.12 billion by 2030

The biomarker technologies market is projected to climb from $64.03 billion in 2026 to $103.12 billion by 2030 as personalized medicine, molecular diagnostics and point-of-care testing gain traction. North America led the market in 2025, while Asia-Pacific is expected to grow fastest during the forecast period.

Why it matters: - Biomarker technologies are becoming central to how healthcare providers detect disease, choose treatments and track patient response. - The market’s growth reflects wider use of personalized medicine, minimally invasive diagnostics and multi-omics research. - Rising demand matters for drug developers, clinical labs and diagnostics firms tied to precision medicine workflows.

What happened: - The Business Research Company released its Biomarker Technologies Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Sept. 16, 2026. - The report projects the biomarker technologies market will rise from $56.62 billion in 2025 to $64.03 billion in 2026. - The report forecasts the market will reach $103.12 billion by 2030. - The report places the market on a 13.1% CAGR from 2025 to 2026 and a 12.7% CAGR from 2026 to 2030. - The Business Research Company offers a free sample of the market report and the full biomarker technologies market report.

The details: - Biomarker technologies cover tools and analytical methods that detect and quantify biological markers in the body. - The technologies analyze blood, tissue, urine and saliva samples. - The report highlights genomics, proteomics, metabolomics and molecular diagnostics as core approaches. - The tools help identify disease indicators, therapeutic responses and physiological changes. - The report says growth is being driven by higher chronic disease prevalence, expanded clinical laboratory infrastructure, more molecular diagnostic testing, stronger pharma R&D spending and greater awareness of early detection. - Future growth is expected to come from broader precision medicine use, stronger demand for minimally invasive diagnostics, more multi-omics research, decentralized and point-of-care testing, and expanded therapy monitoring. - The report points to trends including molecular marker-based early disease detection, preventive health screening, tighter regulatory standardization, large biobanking initiatives and integrated testing workflows across blood, urine and saliva.

Between the lines: - Personalized medicine is becoming a stronger commercial engine for biomarker testing because targeted therapies depend on identifying the right patients. - In February 2024, the Personalized Medicine Coalition said the US Food and Drug Administration approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. - That jump suggests biomarker-linked treatment development is moving deeper into routine drug development and approval pathways. - North America held the largest market share in 2025 because of established healthcare infrastructure and heavy R&D investment. - Asia-Pacific is expected to be the fastest-growing region during the forecast period, signaling shifting demand in diagnostics and lab capacity.

What's next: - The market is expected to keep expanding as precision medicine and minimally invasive testing become more common in clinical practice. - The report flags updated market tools for 2026, including TAM analysis, company scoring matrices, dashboards, infographics and refreshed graphics and tables. - The Business Research Company is promoting direct contact with its expert team for buyers seeking more detail on regional and segment trends.

The bottom line: - Biomarker technologies are moving from niche research tools to a core layer of modern diagnostics and treatment selection, with the fastest growth likely to come from precision medicine adoption and broader testing access.